Abstract
BackgroundCheckpoint inhibitors are a class of agents that employ host’s adaptive immune defenses in fighting cancer. With many new indications and several ongoing clinical trials in a variety of malignancies,...
Highlights
Checkpoint inhibitors are a class of agents that employ host’s adaptive immune defenses in fighting cancer
Nivolumab is among a class of checkpoint inhibitors, which share the same mechanism of enhancing host immunity against tumor cells
With respect to recurrent effusions in patient 1, we considered the possibilities of immune-related Adverse Effect (irAE) vs. pseudoprogression initially; as the patient was otherwise doing well clinically, we were able to manage his recurrent effusions with repeated fluid aspirations while following him closely
Summary
Patients with history of malignant involvement of visceral spaces should be monitored closely for rapidly accumulating effusions and for cardiac tamponade, after initiation of therapy with nivolumab.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
